WHO ICTRP trial
A Phase Ib Study to Evaluate the Safety and Tolerability of Durvalumab and…
JPRN-jRCT2080223710 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-jRCT2080223710 |
|---|---|
| Public title | A Phase Ib Study to Evaluate the Safety and Tolerability of Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Patients With Advanced Solid Tumors. |
| Scientific title | A Phase Ib Study to Evaluate the Safety and Tolerability of Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Patients With Advanced Solid Tumors. |
| Primary sponsor | AstraZeneca |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 1 |
| Countries | Japan;Asia except Japan |
| Conditions | Small Cell Lung Carcinoma / Carcinoma, Squamous Cell of Head and Neck / Stomach Neoplasms / Triple Negative Breast Neoplasms / Ovarian Neoplasms / Fallopian Tube Neoplasms / Peritoneal Neoplasms / Esophagogastric Junction Neoplasms /… |
| Interventions | investigational material(s) Generic name etc : Cohort 1 Drug: paclitaxel + carboplatin, durvalumab, tremelimumab INN of investigational material : - Therapeutic category code : 429 Other antitumor agents Dosage and Administration for… |
| Registration date | Oct 11, 2017 |
| Target size | 22 |
| Secondary IDs | NCT02658214;JapicCTI-173766 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: